Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer

Francesco Grossi, Cesare Gridelli, Marianna Aita, Filippo De Marinis

Research output: Contribution to journalArticlepeer-review


Owing to the slow but sustained progress made in lung cancer treatment over the last 20 years, several therapeutic options are now available in the first-line setting as well as for patients who have progressed after one or more previous lines of treatment. Considering the growing array of choices currently confronting clinicians involved in the treatment of advanced non-small cell lung cancer (NSCLC), an effort should be made to define the optimal treatment option in each disease setting and to identify a logical therapeutic strategy after initial disease progression. This is especially crucial in the management of young, fit patients, who may be suitable candidates for two or more lines of therapy. At present, a rational treatment strategy for advanced NSCLC may be designed on the basis of patient clinicopathological features and rely on evidence from large, well-conducted clinical trials. In a near future the results of prospective validation studies will provide more sophisticated approaches for the classification of lung cancer patients, allowing clinicians to make individualised treatment decisions based on tumour molecular profile and on novel, more refined predictive/prognostic factors.

Original languageEnglish
Pages (from-to)16-26
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Issue number1
Publication statusPublished - Jul 2008


  • Advanced non-small cell lung cancer
  • Biological drugs
  • First-line chemotherapy
  • Second-line therapy
  • Third-line therapy
  • Treatment strategy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this